24 July 2018
Visiongain’ has launched a new pharma report Global Ophthalmic Drugs Market Forecast 2018-2028: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs
Ophthalmic pharmaceuticals are pharmaceutical agents used to treat eye diseases, such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, ocular allergies, infections, inflammatory conditions and dry eye. A specialist sector within the overall pharmaceutical industry, the ophthalmic drugs market is dominated by a relatively small number of companies. The market is relatively mature though with opportunities for growth in key therapeutic areas.
The lead analyst of the report commented “For many indications, the advantages of pharmaceutical treatment far outweigh the benefits offered by alternative treatments such as surgery. As glaucoma, retinal disorders, inflammatory conditions and moderate to severe dry eye require management by medical professionals, the preferred treatment will be largely guided by clinical considerations rather than competition between alternative treatments.
Gene therapies and other regenerative medicine approaches to ophthalmic diseases may become effective substitutes towards the end of the forecast period. The area of gene therapy is still in its infancy with only a handful of currently marketed products. There is much research interest in gene therapies for conditions such as Leber’s congenital amaurosis and retinitis pigmentosa.”
Leading companies featured in the report include Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer, Senju
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The colon targeting drug delivery market has been used various polymers including biodegradable polymers, guar gum, pectin, chondroitin sulfate, dextran, chitosan, cyclodextrin, inulin, amylose, locust bean gum, and others
23 September 2019
Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.
20 September 2019
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.